These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 9968)

  • 1. Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol.
    Richards DA; Tuckman J; Prichard BN
    Br J Clin Pharmacol; 1976 Oct; 3(5):849-55. PubMed ID: 9968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological basis for antihypertensive effects of intravenous labetalol.
    Richards DA; Prichard BN; Boakes AJ; Tuckman J; Knight EJ
    Br Heart J; 1977 Jan; 39(1):99-106. PubMed ID: 12778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties.
    Elliott HL; McLean K; Meredith PA; Sumner DJ; Reid JL
    Br J Clin Pharmacol; 1984 May; 17(5):565-72. PubMed ID: 6145440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationships between the cardiovascular effects, alpha- and beta-adrenoceptor blocking actions and plasma concentration of labetalol in doca hypertensive rats.
    Drew GM; Hilditch A; Levy GP
    Clin Exp Hypertens (1978); 1979; 1(5):597-611. PubMed ID: 42517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.
    Brittain RT; Levy GP
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):681-4. PubMed ID: 10948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers.
    Riva E; Mennini T; Latini R
    Br J Pharmacol; 1991 Dec; 104(4):823-8. PubMed ID: 1687367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autonomic and antihypertensive activity of oral amosulalol (YM-09538), a combined alpha- and beta-adrenoceptor blocking agent in conscious rats.
    Honda K; Takenaka T; Shiono K; Miyata-Osawa A; Nakagawa C
    Jpn J Pharmacol; 1985 May; 38(1):31-41. PubMed ID: 2862302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological effects of labetalol in man.
    Richards DA
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):721-3. PubMed ID: 10949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-adrenoceptor blockade by labetalol during long-term dosing.
    Semplicini A; Pessina AC; Rossi GP; Hlede M; Morandin F
    Clin Pharmacol Ther; 1983 Mar; 33(3):278-82. PubMed ID: 6130864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent antagonism of isoproterenol and norepinephrine after labetalol.
    Richards DA; Prichard BN
    Clin Pharmacol Ther; 1978 Mar; 23(3):253-8. PubMed ID: 627129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of adimolol, labetalol and propranolol on heart rate and blood pressure in man.
    Riddell JG; Harron DW; Shanks RG
    Br J Clin Pharmacol; 1985 Apr; 19(4):405-10. PubMed ID: 2859871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. beta- and alpha-Adrenoceptor antagonism by medroxalol in healthy volunteers: relationship to dose and plasma concentration.
    Jaillon P; Weissenburger J; Biour M; Cheymol G; Haegele K; Schechter PJ; Koch-Weser J
    J Cardiovasc Pharmacol; 1982; 4(5):705-13. PubMed ID: 6182399
    [No Abstract]   [Full Text] [Related]  

  • 13. Alpha- and beta-adrenoceptor blocking properties of labetalol in renin release.
    Lammintausta R; Koulu M; Allonen H
    Int J Clin Pharmacol Biopharm; 1979 Jun; 17(6):240-43. PubMed ID: 38214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between plasma concentrations and pharmacological effects of labetalol.
    Richards DA; Maconochie JG; Bland RE; Hopkins R; Woodings EP; Martin LE
    Eur J Clin Pharmacol; 1977 Jan; 11(2):85-90. PubMed ID: 14010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha and beta adrenoceptor blocking properties of labetalol and its R,R-isomer, SCH 19927.
    Sybertz EJ; Sabin CS; Pula KK; Vliet GV; Glennon J; Gold EH; Baum T
    J Pharmacol Exp Ther; 1981 Aug; 218(2):435-43. PubMed ID: 6114171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dose dependency of the alpha-adrenoceptor antagonist and beta-adrenoceptor partial agonist activity of dilevalol and labetalol in man.
    Tham TC; McKaigue JP; Guy S; Shanks RG; Riddell JG
    Br J Clin Pharmacol; 1993 Sep; 36(3):251-6. PubMed ID: 9114912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta blockade by oral propranolol and labetalol.
    Cubeddu LX; Carr ME; Fuenmayor NJ
    Clin Pharmacol Ther; 1985 Mar; 37(3):277-83. PubMed ID: 2857602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined alpha- and beta-adrenoceptor blocking drug AH 5158: further studies on alpha-adrenoceptor blockade in anaesthetized animals.
    Kennedy I; Levy GP
    Br J Pharmacol; 1975 Apr; 53(4):585-92. PubMed ID: 238705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man.
    Tham TC; Guy S; McDermott BJ; Shanks RG; Riddell JG
    Br J Clin Pharmacol; 1995 Jul; 40(1):19-23. PubMed ID: 8527263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the R, R-isomer of labetalol, SCH 19927, in isolated tissues and in spontaneously hypertensive rats during a repeated treatment.
    Monopoli A; Bamonte F; Forlani A; Ongini E; Parravicini L
    Arch Int Pharmacodyn Ther; 1984 Dec; 272(2):256-63. PubMed ID: 6151824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.